G
Geerard L. Beets
Researcher at Netherlands Cancer Institute
Publications - 311
Citations - 18117
Geerard L. Beets is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 61, co-authored 270 publications receiving 14472 citations. Previous affiliations of Geerard L. Beets include Tibotec & Champalimaud Foundation.
Papers
More filters
Journal ArticleDOI
Global variation in the long-term outcomes of ypT0 rectal cancers
Laura Lorenzon,Serge Evrard,Geerard L. Beets,Santiago González-Moreno,Tibor Kovacs,Domenico D'Ugo,Karol Polom +6 more
TL;DR: An international cohort study enrolling ypT0/ypTis rectal cancers surgically treated from 2012 to 2017 and identifying sub-groups at risk for relapses and nodal metastasis found a global variation when benchmarking a rectal cancer complete regression.
Journal ArticleDOI
Colorectal cancer immunotherapy: a treatment quantum leap.
Journal Article
Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumour and metastases in primary stage iv rectal cancer: a phase ii multicenter study of the dutch colorectal cancer group
T. H. van Dijk,Geesiena Hospers,J. C. Beukema,Geerard L. Beets,A. J. Gelderblom,K. P. de Jong,H.J.T. Rutten,C.J.H. van de Velde,T. Wiggers,Klaas Havenga +9 more
TL;DR: In this paper, the authors conducted a phase II study to test the efficacy of 5x5 Gy to the pelvic followed by 6 cycli chemotherapy and re-constant cyclic chemotherapy.
Journal ArticleDOI
3005 ORAL Can we predict the nodal status in primary rectal cancer accurately with USPIO MRI
Geerard L. Beets,M. J. Lahaye,Sanne M. E. Engelen,A.P. de Bruine,M.F. von Meyenfeldt,J.M.A. van Engelshoven,C.J.H. van de Velde,R.G.H. Beets-Tan +7 more
Journal ArticleDOI
Gastrointestinal cancer: Which way is forward in the treatment of rectal cancer?
TL;DR: Preoperative 5-fluorouracil-based chemoradiation with optimal surgery provides very effective local control in locally advanced rectal cancer and adding oxaliplatin as a radiosensitizer provides any additional benefit.